Microarray analysis of papillary thyroid cancers in Korean

Korean Journal of Internal Medicine

Volumn 25, Issue 4, 2010, Pages 399-407

  Kim, Hyun Sook ^a   Kim, Do Hyung ^b   Kim, Ji Yeon ^a   Jeoung, Nam Ho ^a   Lee, In Kyu ^b   Bong, Jin Gu ^a   Jung, Eui Dal ^a  

^a Catholic University of Daegu   (South Korea)

^b Kyungpook National University School of Medicine   (South Korea)

Author keywords

BRAF mutation; FOXA2 protein; Human; Oligonucleotide array sequence analysis; Thyroid cancer

Indexed keywords

B RAF KINASE; CARRIER PROTEINS AND BINDING PROTEINS; CARTILAGE OLIGOMERIC MATRIX PROTEIN; COMPLEMENTARY DNA; HEPATOCYTE NUCLEAR FACTOR 3BETA; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR2.1; KALLIKREIN; KALLIKREIN RELATED PEPTIDASE 7; LYMPHATIC VESSEL ENDOTHELIAL HYALURONAN RECEPTOR 1; MEMBRANE PROTEIN; RECEPTOR PROTEIN; SODIUM PHOSPHATE COTRANSPORTER 2B; SOLUTE CARRIER FAMILY 4 SODIUM BICARBONATE COTRANSPORTER MEMBER 4; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR CP2 LIKE 1; TRANSMEMBRANE 7 SUPERFAMILY MEMBER 4 PROTEIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; DNA MICROARRAY; FEMALE; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; GENOTYPE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KOREA; MALE; MICROARRAY ANALYSIS; MUTATIONAL ANALYSIS; PROTEIN LOCALIZATION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THYROID PAPILLARY CARCINOMA;

ADULT; AGED; CARCINOMA, PAPILLARY; FEMALE; GENE EXPRESSION PROFILING; HEPATOCYTE NUCLEAR FACTOR 3-BETA; HUMANS; IMMUNOHISTOCHEMISTRY; KALLIKREINS; KOREA; MALE; MIDDLE AGED; MUTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMERASE CHAIN REACTION; PROTO-ONCOGENE PROTEINS B-RAF; THYROID NEOPLASMS; VESICULAR TRANSPORT PROTEINS;

EID: 78650987470     PISSN: 12263303     EISSN: 20056648     Source Type: Journal    
DOI: 10.3904/kjim.2010.25.4.399     Document Type: Article

References (25)

1. Lind P, Langsteger W, Molnar M, Gallowitsch HJ, Mikosch P, Gomez I. Epidemiology of thyroid diseases in iodine sufficiency. Thyroid 1998;8:1179-1183.
2. Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer 1998;83:2638-2648.
3. Gimm O. Thyroid cancer. Cancer Lett 2001;163:143-156.
4. Neff RL, Farrar WB, Kloos RT, Burman KD. Anaplastic thyroid cancer. Endocrinol Metab Clin North Am 2008;37:525-538, xi.
5. McIver B, Hay ID, Giuffrida DF, et al. Anaplastic thyroid carcinoma: a 50-year experience at a single institution. Surgery 2001;130:1028-1034.
6. Kinder BK. Well differentiated thyroid cancer. Curr Opin Oncol 2003;15:71-77.
7. Kondo T, Ezzat S, Asa SL. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 2006;6:292-306.
8. Kim KH, Kang DW, Kim SH, Seong IO, Kang DY. Mutations of the BRAF gene in papillary thyroid carcinoma in a Korean population. Yonsei Med J 2004;45:818-821.
9. Slough CM, Randolph GW. Workup of well-differentiated thyroid carcinoma. Cancer Control 2006;13:99-105.
10. Amrikachi M, Ramzy I, Rubenfeld S, Wheeler TM. Accuracy of fine-needle aspiration of thyroid. Arch Pathol Lab Med 2001;125:484-488.
11. Goellner JR, Gharib H, Grant CS, Johnson DA. Fine needle aspiration cytology of the thyroid, 1980 to 1986. Acta Cytol 1987;31:587-590.
12. Griffith OL, Melck A, Jones SJ, Wiseman SM. Meta-analysis and meta-review of thyroid cancer gene expression profiling studies identifies important diagnostic biomarkers. J Clin Oncol 2006;24:5043-5051.
13. Giordano TJ, Kuick R, Thomas DG, et al. Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene 2005;24:6646-6656.
14. Eszlinger M, Krohn K, Kukulska A, Jarzab B, Paschke R. Perspectives and limitations of microarray-based gene expression profiling of thyroid tumors. Endocr Rev 2007;28:322-338.
15. Hartgers FC, Vissers JL, Looman MW, et al. DC-STAMP, a novel multimembrane-spanning molecule preferentially expressed by dendritic cells. Eur J Immunol 2000;30:3585-3590.
16. Yagi M, Miyamoto T, Sawatani Y, et al. DC-STAMP is essential for cell-cell fusion in osteoclasts and foreign body giant cells. J Exp Med 2005;202:345-351.
17. Lee KY, Huang SM, Li S, Kim JM. Identification of differentially expressed genes in papillary thyroid cancers. Yonsei Med J 2009;50:60-67.
18. Galeza-Kulik M, Zebracka J, Szpak-Ulczok S, et al. Expression of selected genes involved in transport of ions in papillary thyroid carcinoma. Endokrynol Pol 2006;57(Suppl A):26-31.
19. Borgoño CA, Michael IP, Diamandis EP. Human tissue kallikreins: physiologic roles and applications in cancer. Mol Cancer Res 2004;2:257-280.
20. Paliouras M, Borgono C, Diamandis EP. Human tissue kallikreins: the cancer biomarker family. Cancer Lett 2007;249:61-79.
21. Talieri M, Mathioudaki K, Prezas P, et al. Clinical significance of kallikrein-related peptidase 7 (KLK7) in colorectal cancer. Thromb Haemost 2009;101:741-747.
22. Arden KC. Multiple roles of FOXO transcription factors in mammalian cells point to multiple roles in cancer. Exp Gerontol 2006;41:709-717.
23. Reagan-Shaw S, Ahmad N. The role of Forkhead-box Class O (FoxO) transcription factors in cancer: a target for the management of cancer. Toxicol Appl Pharmacol 2007;224:360-368.
24. Karger S, Weidinger C, Krause K, et al. FOXO3a: a novel player in thyroid carcinogenesis? Endocr Relat Cancer 2009;16:189-199.
25. Akagi T, Luong QT, Gui D, et al. Induction of sodium iodide symporter gene and molecular characterisation of HNF3 beta/FoxA2, TTF-1 and C/EBP beta in thyroid carcinoma cells. Br J Cancer 2008;99:781-788.